JBTM vs MIDD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JBTM presents a stark contrast between explosive top-line growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 2/9. While revenue growth is exceptional at 115.60% YoY and analysts maintain a bullish target price of $183.50, the company is currently struggling with negative profit margins (-1.33%) and negative ROE (-1.65%). Liquidity is a concern with a Quick Ratio of 0.45, and insider sentiment is bearish with significant selling by the CEO and Directors. The stock is a high-growth play with significant underlying financial instability.
The Middleby Corporation presents a conflicted profile: a stable Piotroski F-Score of 4/9 and strong liquidity (Current Ratio 2.57) are offset by severe short-term growth contraction. The stock is trading at a significant premium to its Graham Number ($94.81) and Intrinsic Value ($49.28), suggesting the market is pricing in a recovery not yet reflected in the data. While operating margins remain healthy at 18.81%, the negative net profit margin and sharp declines in YoY revenue and earnings growth are primary concerns.
Compare Another Pair
Related Comparisons
JBTM vs MIDD: Head-to-Head Comparison
This page compares JBT Marel Corporation (JBTM) and The Middleby Corporation (MIDD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.